Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06221553 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

Study acronym: CMD03DIPG
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site contact updatedv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chulalongkorn University
67 trials monitored
See 1 trial at risk
Glioma
1,251 trials monitored
See 88 trials at risk
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
Trial Details
NCT Number NCT06221553
Lead Sponsor Chulalongkorn University
Collaborators: King Chulalongkorn Memorial Hospital
Conditions
(from sponsor)		 DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Related terms Diffuse Intrinsic Pontine Glioma
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov